Lexicon (company)

Lexicon (company) is a biotechnology company that focuses on the discovery and development of innovative treatments for various diseases, including diabetes, cancer, and cardiovascular disease. The company was founded in 1995 by Arthur M. Pappas and Brian Z. Ring, and it is headquartered in The Woodlands, Texas, near Houston. Lexicon has collaborated with several major pharmaceutical companies, including Bristol-Myers Squibb, Merck & Co., and GlaxoSmithKline, to develop new treatments for various diseases. The company's research and development efforts have been supported by investments from Venture capital firms, such as Domain Associates and OrbiMed.

● History

The history of Lexicon dates back to 1995, when it was founded by Arthur M. Pappas and Brian Z. Ring. Initially, the company focused on the development of genomics-based technologies, including DNA sequencing and gene expression analysis. In the early 2000s, Lexicon began to shift its focus towards the discovery and development of small molecule therapies, including kinase inhibitors and G protein-coupled receptor modulators. The company has received funding from various sources, including National Institutes of Health grants and investments from venture capital firms, such as Domain Associates and OrbiMed. Lexicon has also collaborated with several academic institutions, including Harvard University, Stanford University, and University of California, San Francisco, to advance its research and development efforts.

● Products

Lexicon has developed several products, including telotristat ethyl, a treatment for carcinoid syndrome, which was approved by the US Food and Drug Administration in 2017. The company has also developed sotagliflozin, a treatment for type 1 diabetes, which is currently in clinical trials. Lexicon's product pipeline includes several other candidates, including LX9211, a treatment for neuropathic pain, and LX2761, a treatment for cancer. The company's products have been developed in collaboration with several major pharmaceutical companies, including Sanofi and Bristol-Myers Squibb. Lexicon has also partnered with several biotechnology companies, including Illumina and Agilent Technologies, to develop new technologies and products.

● Technology

Lexicon's technology platform is based on its expertise in genomics, proteomics, and bioinformatics. The company has developed several proprietary technologies, including its gene trapping platform, which allows for the rapid identification of gene function and the discovery of new drug targets. Lexicon has also developed several high-throughput screening platforms, including its kinase inhibitor platform, which allows for the rapid identification of small molecule inhibitors of kinases. The company's technology platform has been used to develop several products, including telotristat ethyl and sotagliflozin. Lexicon has collaborated with several academic institutions, including Massachusetts Institute of Technology and University of California, Berkeley, to advance its technology platform.

● Acquisitions_and_Partnerships

Lexicon has formed several partnerships and collaborations with major pharmaceutical companies, including Bristol-Myers Squibb, Merck & Co., and GlaxoSmithKline. The company has also partnered with several biotechnology companies, including Illumina and Agilent Technologies, to develop new technologies and products. In 2019, Lexicon was acquired by Sanofi for $3.4 billion. The acquisition expanded Sanofi's portfolio of treatments for various diseases, including diabetes and cancer. Lexicon has also collaborated with several academic institutions, including Harvard University and Stanford University, to advance its research and development efforts. The company has received funding from various sources, including National Institutes of Health grants and investments from venture capital firms, such as Domain Associates and OrbiMed.

● Company_Overview

Lexicon is a biotechnology company that focuses on the discovery and development of innovative treatments for various diseases. The company was founded in 1995 and is headquartered in The Woodlands, Texas. Lexicon has a strong research and development pipeline, with several products in clinical trials. The company's products have been developed in collaboration with several major pharmaceutical companies, including Sanofi and Bristol-Myers Squibb. Lexicon has also partnered with several biotechnology companies, including Illumina and Agilent Technologies, to develop new technologies and products. The company's management team includes several experienced executives, including Lonnel Coats, who has previously worked at Eli Lilly and Company and Pfizer.

● Financial_Information

Lexicon's financial performance has been strong in recent years, with revenues increasing significantly due to the approval and commercialization of its products, including telotristat ethyl. The company has received funding from various sources, including National Institutes of Health grants and investments from venture capital firms, such as Domain Associates and OrbiMed. In 2019, Lexicon was acquired by Sanofi for $3.4 billion, which expanded Sanofi's portfolio of treatments for various diseases. The acquisition was financed through a combination of cash and debt, and it is expected to be accretive to Sanofi's earnings per share. Lexicon's financial performance has been influenced by several factors, including the performance of its products, the outcome of its clinical trials, and the overall state of the biotechnology industry, which is influenced by companies such as Amgen, Gilead Sciences, and Biogen. Category:Biotechnology companies